Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

被引：0
|
作者：
Vitale, Pasquale [1 ]
De Falco, Vincenzo [1 ]
Addeo, Raffaele [1 ,2 ]
机构：
[1] Hosp Frattamaggiore, Oncol Operat Unit, Frattamaggiore, Italy
[2] ASLNA2NORD, San Giovanni Dio Hosp, Oncol Operat Unit, Via D Pirozzi 62, I-80027 Frattamaggiore, NA, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 07期
关键词：
Recurrent/metastatic head and neck cancer; cetuximab; PD-L1; pembrolizumab; chemotherapy; combined positive score; SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; RECURRENT; PEMBROLIZUMAB; KEYNOTE-048;
D O I：
10.1080/14737140.2024.2354772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：481 / 484
页数：4
相关论文
共 50 条
  • [41] Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data
    Patachi, Bogdana
    Jensen, Kristian H.
    Gothelf, Anita
    Bernsdorf, Mogens
    Friborg, Jeppe
    Kristensen, Claus A.
    ACTA ONCOLOGICA, 2025, 64 : 143 - 146
  • [42] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob Stephen
    Bruce, Justine Yang
    Li, Zujun
    Lorch, Jochen H.
    Phillips, Tanyanika
    Villaflor, Victoria
    Ruel, Christopher
    Palmer, Joycelynne
    Gutkind, J. Silvio
    Villalona-Calero, Miguel Angel
    Colevas, Alexander Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    Szturz, Petr
    Seiwert, Tanguy Y.
    Vermorken, Jan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (20) : 2229 - +
  • [44] Efficacy and safety of pembrolizumab in recurrent or metastatic head and neck carcinoma as first-line therapy
    Ito, K.
    Nakanome, A.
    Morita, S.
    Imai, T.
    Asada, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1402 - S1402
  • [45] CETUXIMAB IN COMBINATION WITH XELIRI OR XELOX IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Mesti, Tanja
    Moltara, Maja Ebert
    ANNALS OF ONCOLOGY, 2011, 22 : v96 - v96
  • [46] First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab
    Tonini, Giuseppe
    Calvieri, Alice
    Vincenzi, Bruno
    Santini, Daniele
    ONCOTARGETS AND THERAPY, 2009, 2 : 73 - 82
  • [47] Cetuximab A Guide to Its Use in Combination with FOLFIRI in the First-Line Treatment of Metastatic Colorectal Cancer in the USA
    Lyseng-Williamson, Katherine A.
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (05) : 317 - 322
  • [48] First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
    Shunji Takahashi
    Nobuhiko Oridate
    Kaoru Tanaka
    Yasushi Shimizu
    Yasushi Fujimoto
    Koji Matsumoto
    Tomoya Yokota
    Tomoko Yamazaki
    Masanobu Takahashi
    Tsutomu Ueda
    Nobuhiro Hanai
    Hironori Yamaguchi
    Hiroki Hara
    Tomokazu Yoshizaki
    Ryuji Yasumatsu
    Masahiro Nakayama
    Kiyoto Shiga
    Takashi Fujii
    Kenji Mitsugi
    Kenichi Takahashi
    Nijiro Nohata
    Burak Gumuscu
    Ramona F. Swaby
    Makato Tahara
    International Journal of Clinical Oncology, 2022, 27 : 1805 - 1817
  • [49] First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
    Takahashi, Shunji
    Oridate, Nobuhiko
    Tanaka, Kaoru
    Shimizu, Yasushi
    Fujimoto, Yasushi
    Matsumoto, Koji
    Yokota, Tomoya
    Yamazaki, Tomoko
    Takahashi, Masanobu
    Ueda, Tsutomu
    Hanai, Nobuhiro
    Yamaguchi, Hironori
    Hara, Hiroki
    Yoshizaki, Tomokazu
    Yasumatsu, Ryuji
    Nakayama, Masahiro
    Shiga, Kiyoto
    Fujii, Takashi
    Mitsugi, Kenji
    Takahashi, Kenichi
    Nohata, Nijiro
    Gumuscu, Burak
    Swaby, Ramona F.
    Tahara, Makato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1805 - 1817
  • [50] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
12345